Podcasts about Biotechnology

GUEST:   https://www.instagram.com/iamtero/?hl=en   https://hirodiapers.com/   MENTIONS:   https://en.wikipedia.org/wiki/Pestalotiopsis_microspora   MUSHROOM HOUR:   https://welcometomushroomhour.com   https://www.instagram.com/mushroomhourpodcast   https://tiktok.com/@welcome_to_mushroom_hour   Show Music courtesy of the one and only Chris Peck: https://peckthetowncrier.bandcamp.com/   TOPICS COVERED:   Raised around Regenerative Ideology   Diapers as Ubiquitous Household Waste   Fungi Decomposing Plastic   Training Mushrooms to Eat Different Foods   Ligninolytic Enzymes   Challenges of Weather and Competition   Researching, Developing and Testing Mushroom Species  Regulations in Waste Management or Lack Thereof   How does the Hiro Diaper Work?   Working with Existing Industries   Gene Editing and Ethical Dilemmas   

(14) Jack Burnham explains that Volvo, though manufacturing in the US, is owned by Geely and must comply with Chinese data-sharing laws. He also warns of China's dominance in the biotechnology supply chain. Through state subsidies and "dumping," China threatens the security of US pharmaceutical and generic drug stockpiles.

Jessica has had a cool path in biochemistry, with work in both academia and industry, as well as an internship at the National Institutes of Health. She is the Director of New Product Development at LCG Clinical Diagnostics, where she oversees the R&D department. In addition to her work at LCG Clinical Diagnostics, Jessica has been an enthusiastic volunteer for both the Maine Science Festival and the Bioscience Association of Maine's Bioscience Day. This conversation was recorded in May 2026. ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky YouTubeMaine Science Podcast on social media: Facebook Instagram YouTubeMaine Science Festival on social media: Facebook Instagram LinkedIn YouTube© 2026 Maine Discovery Museum

Purti Kanodia Talks Real-World AI Applications. On this episode of OWA Talks, Purti shares a practical, no-hype approach to building AI fluency. Join us as we get beyond the ‘theory' and talk implementation. If you're curious about AI but overwhelmed, this one's for you.About the guest:Purti Kanodia is a fractional AI transformation leader and founder of Clarity Prompts, an AI consulting firm and weekly newsletter that helps executives and senior leaders build AI fluency and lead practical, responsible AI adoption across their organizations.With nearly two decades of experience across optical retail, employer healthcare, management consulting, and biopharma, Purti has worked with companies including National Vision, Crossover Health, Slalom Consulting, and Genentech, always at the intersection of technology, business strategy, and human change. At National Vision, she led the launch of Toku BioAge, the first AI-based retinal imaging wellness product in US optical retail. Earlier at Slalom Consulting, she spent two years in Ophthalmology designing product strategy for AI/ML clinical decision support tools.What sets Purti apart is her whole-picture lens on technology adoption. She starts with the problem, not the technology, and believes that testing without measurement rarely survives the pilot. Getting to real scale means thinking through people, process, and organizational readiness together, not as an afterthought.She has mentored startups through Singularity University Labs, the UCSF Entrepreneurship Center, and HealthTech Capital. Purti holds a Master of Science in Biotechnology from Georgetown University and is based in the San Francisco Bay Area.Like this episode? Please subscribe and share!iTunes | Spotify | Overcast | iHeartRadio | AmazonConnect with the OWA:Website | LinkedIn | Instagram | Facebook

What if the future of longevity is less about living longer and more about living better? In the latest episode of Let's Talk Future, Jane Ross speaks with Jay Olson, CFA, Managing Director and Senior Analyst covering Biotechnology at Oppenheimer, about the biotech innovations shaping healthy aging. The conversation explores GLP-1 obesity drugs, preventive medicine, muscle preservation, inflammation, diagnostics, and personalized therapies — and how these developments could help redefine health span.© 2026 Oppenheimer & Co. Inc. Transacts Business on All Principal US Exchanges and is a Member of SIPC. 8942277.1

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

In some of our previous episodes, we've explored the interesting paths that  Wolf Greenfield attorneys have taken as they eventually made their way to IP law. One thing that separates Wolf Greenfield from other firms is the depth of real-world experience many of its attorneys possess. In fact, over half of the professionals at Wolf Greenfield worked in science and technology industries prior to entering law.Kevin MacDonald, a Shareholder in Wolf Greenfield's Biotechnology practice, is an ideal example. After earning a degree in biology at Boston College, Kevin went to England to get his Master's in Molecular Biology and then back to North America for his PhD at McGill University's Institute of Parasitology in Montreal. Before his graduate studies and eventually going to law school, Kevin worked as a Life Science and Healthcare Industry Analyst at the British Consulate-General in Boston.In this episode of IP Talk with Wolf Greenfield,  Kevin discusses his path from the world of science to IP law and his current work assisting clients with IP strategy, portfolio management, and patent prosecution and counseling.Here are a few highlights from the conversation:01:18 - Kevin's background in biology02:33 - How Kevin became interested in parasitology03:10 - Serving as an analyst at the British Consulate-General04:21 - Making the switch to law05:38 - The challenges of transitioning from science to a legal career06:21 - Kevin's current practice at Wolf Greenfield07:20 - Some of the most exciting things happening in biopharma today08:18 - Kevin's efforts as a board member of the British American Business Council of New England###

Lien vers la ⚜️Guilde Tinctoriale⚜️Êtes-vous prêt à plonger dans l'univers fascinant des couleurs végétales et des plantes tinctoriales ? Dans cet épisode captivant du podcast ArtEcoVert, nous avons le plaisir d'accueillir Pauline Leroux, ingénieure agronome passionnée et fervente défenseure de la couleur du vivant. Elle nous entraîne dans un voyage à travers les initiatives innovantes qui visent à promouvoir la richesse des teintes naturelles issues des plantes tinctoriales.Au fil de la conversation, Pauline partage le parcours inspirant des agriculteurs et agricultrices qui se consacrent à la production de ces plantes fascinantes. Quels sont les défis auxquels ils font face ? Quelles opportunités s'offrent à eux dans ce secteur en pleine expansion ? Découvrez les réponses à ces questions tout en explorant le lancement de la Guilde Tinctoriale, un réseau dynamique conçu pour rassembler les acteurs de la couleur végétale. Ce réseau a pour objectif de faciliter les échanges entre producteurs et utilisateurs, tout en mettant en avant l'importance de la mutualisation des ressources et de la formation.Les experts de la guilde, comprenant des agricultrices expérimentées, accompagneront les membres tout au long de l'année, offrant ainsi un soutien précieux pour développer leurs activités. Ensemble, ils réfléchiront à la valorisation des prix agricoles et à l'établissement de relations durables entre les différents acteurs de la filière. Comme le souligne Pauline : "La couleur du vivant mérite d'être célébrée et soutenue."En rejoignant la Guilde Tinctoriale, vous aurez accès à un réseau de soutien et de ressources partagées, vous permettant de vous connecter avec d'autres passionnés et professionnels du secteur. Cet épisode est une invitation à s'engager pour un avenir coloré et durable, où les savoir-faire traditionnels se mêlent à l'innovation.Pour ceux qui souhaitent approfondir leur connaissance des plantes tinctoriales et de la couleur végétale, cet épisode est un incontournable. N'attendez plus pour découvrir comment vous pouvez contribuer à cette belle aventure et faire partie de ce mouvement essentiel. Rejoignez-nous et laissez-vous inspirer par les histoires et les expériences partagées dans ArtEcoVert !Pour plus d'informations et de ressources, n'hésitez pas à consulter les liens utiles mentionnés dans l'épisode. Belle écoute !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

50 % des médicaments actuellement en phase de développement sont des biomédicaments. Un chiffre qui illustre l'ampleur d'une révolution thérapeutique… et industrielle. Car produire à partir du vivant, c'est composer avec des bioprocédés complexes, parfois imprévisibles et des coûts de production qui conditionnent directement l'accès aux soins. Déjà, certains traitements restent inaccessibles en Europe faute d'industrialisation locale, faisant de la bioproduction un enjeu majeur de souveraineté sanitaire autant qu'économique.À la croisée du vivant, de l'ingénierie de précision et de l'économie de la santé, le défi est désormais clair : passer à l'échelle et en France pour permettre aux thérapies géniques et cellulaires de tenir leurs promesses.Dans cet épisode d'Écoutons le Futur, nos invités évoquent l'ensemble des maillons de la chaîne. Ils reviennent sur la complexité des bioprocédés, ainsi que sur le rôle de l'IA et des outils numériques pour les rendre plus robustes et prédictibles. Le tout dans le but de bâtir une filière capable de transformer l'excellence scientifique française en puissance industrielle au service des patients.Présents sur notre plateau :- Victor Pozzobon​, Responsable de l'équipe modélisation de la Chaire de Biotechnologie de CentraleSupélec​- Timothé Cynober​, Directeur du développement ​chez WhiteLab Genomics ​- Laurent Lafferrère, ​​Directeur Général chez France BioLead​​- Maxime Mock, Data scientist chez Capgemini Engineering​ Une émission animée par Valère Corréard

Aujourd'hui dans "Les voix de l'économie", Stéphane Pedrazzi reçoit le docteur Philippe Pouletty, investisseur et chercheur en biologie moléculaire, qui partage son expertise sur les enjeux cruciaux auxquels le monde fait face en matière de santé publique. Alors que l'Organisation mondiale de la santé se réunit pour discuter des épidémies d'Ebola et d'hantavirus, le docteur alerte sur la nécessité de se préparer à une « biodéfense stratégique » face à la recrudescence des pandémies virales. Avec une vision à la fois pragmatique et visionnaire, il souligne que ces crises sanitaires seront de plus en plus fréquentes, à l'instar des catastrophes naturelles. Revenant sur les leçons tirées de la pandémie de Covid-19, Philippe Pouletty pointe du doigt les lacunes de l'industrie pharmaceutique traditionnelle, incapable de réagir avec la célérité requise. C'est finalement grâce à l'innovation portée par les biotechs, comme Moderna aux États-Unis ou BioNTech en Allemagne, que la planète a pu être protégée. Mais ce constat soulève une autre problématique : le manque de financement dont souffrent ces pépites de la biotech en Europe. Malgré des succès comme Abivax, valorisée à 10 milliards de dollars, l'invité i déplore le « plafond de verre » qui freine l'émergence de champions européens face à la domination américaine et asiatique.Au-delà des vaccins, il met en lumière une alternative prometteuse : les anticorps monoclonaux développés par sa propre entreprise, SpikImm, en collaboration avec l'Institut Pasteur. Grâce à l'intelligence artificielle, ces molécules de haute affinité pourraient offrir une protection rapide et durable en cas de nouvelle pandémie.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

It's been over 25 years since the FDA approved a new ingredient for sunscreen in the United States. But a molecule called gadusol found in fish and coral reefs is a promising candidate. It absorbs U.V. rays — acting like a built-in sunscreen for fish. But there's a big hurdle if scientists want to turn gadusol into human sunscreen: They'd need to make a lot of it. A new study out this week in the journal Trends in Biotechnology takes us a big step closer. Their solution? Using the bacteria best known for making your stomach hurt: e. Coli. Interested in more science? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Podcast, reveals how traditional "one factor at a time" screening in biosimilar development can take over 12 months, while the parallel group design massively accelerates discovery by grouping up to five factors per experiment and applying a multivariate analysis pipeline.Topics discussed:The limitations of traditional and large DoE designs and the advantages of parallel group design (00:08)Best practices for grouping compounds by biological mechanism with four essential rules (00:53)The importance of anchor compounds, separating strong modulators, and initial univariate screens for unknown compounds (01:43)Guidance on managing practical issues, including evaporation, liquid handling, osmolality, and replicating production processes (06:42)The use of multivariate analysis tools: Principal Component Analysis, Mahalanobis distance, and decision trees for candidate selection (10:14)Key results and outcomes from applying the parallel group method, including faster and more cost-effective quality modulator identification (12:46)Three improvements David would recommend today: prequalifying compounds, broader quality analytics, and hybrid modeling integration (13:49)The shift in mindset from “time problem” to “information problem” in process development (16:50)Extending the parallel group and multivariate approach to other areas like clone selection and scale-up decisions (17:52)Smart insight:Process development is fundamentally about generating actionable information, not just running more experiments. The parallel group, multivariate pipeline lets teams ask better questions, in parallel, with dramatically improved data yield. This mindset and methodology extend well beyond biosimilar media development into clone selection, feed design, and process characterization, wherever complexity would paralyze traditional approaches.If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.If you're interested in hybrid modeling, here's what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian FeidlEpisodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi QuintEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.Support the show

*« développement de niche et minima de prod chez Mediplant » : ce ne sont pas 3000L, mais par exemple 2000-3000 cannettes en ce qui concerne les boissons, une centaine d'unités pour des produits cosmétiques et on peut travailler quelques kg de graines pour des essais d'extractions d'huileMédiplant https://www.mediplant.ch/index.php/fr/Quelle est la couleur de notre avenir ? Dans cet épisode captivant d'ArtEcoVert, Pauline Leroux reçoit Audrey Kuhn, une pionnière dans le domaine de la biotechnologie et des plantes tinctoriales. Ensemble, elles plongent dans l'univers fascinant des couleurs végétales, révélant comment ces ressources naturelles peuvent transformer l'artisanat et l'industrie. Audrey, avec son parcours impressionnant allant de la biopharmaceutique à la recherche sur les plantes médicinales et tinctoriales au sein de Mediplan en Suisse, partage ses expériences et ses découvertes.Au fil de cette discussion enrichissante, vous découvrirez l'importance croissante des plantes tinctoriales comme l'indigo des Alpes et l'Orpain Rose. Ces trésors de la nature ne sont pas seulement des sources de couleur, mais aussi des éléments essentiels pour promouvoir une économie durable et respectueuse de l'environnement. Audrey souligne l'impact des recherches agronomiques sur la filière tinctoriale, et comment la collaboration entre acteurs locaux peut valoriser ces ressources précieuses.« Nous devons relier la couleur du vivant aux usages réels », déclare Audrey, insistant sur la nécessité de recréer une souveraineté de la couleur au sein de nos sociétés. Ce besoin est d'autant plus pressant face aux défis du changement climatique qui menacent l'avenir de la culture des plantes tinctoriales en Suisse. Comment pouvons-nous nous engager pour préserver ces savoir-faire ancestraux tout en innovant ?Dans cet épisode, vous aurez un aperçu des défis et des opportunités que présente l'utilisation des couleurs végétales dans notre monde moderne. Les discussions techniques et les partages d'expériences d'Audrey vous inspireront à explorer davantage ce domaine fascinant. Que vous soyez un passionné de l'artisanat, un professionnel de l'industrie ou simplement curieux d'en savoir plus sur les plantes tinctoriales, cet épisode d'ArtEcoVert est fait pour vous.Ne manquez pas cette occasion d'élargir vos horizons et de découvrir comment les couleurs végétales peuvent façonner notre avenir. Pour en savoir plus sur les ressources locales et les initiatives en cours, restez à l'écoute et plongez dans cette aventure colorée ! Belle écoute !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

Send us Fan MailWhat if the next breakthrough cancer therapy can't be manufactured on Earth at all?In this episode, BioOrbit CEO Dr. Katie King explains how microgravity may unlock entirely new classes of medicines - from ultra-precise biologics to cancer therapies manufactured in orbit aboard future pharmaceutical factories in space.Dr. Katie King, Ph.D is a scientist, entrepreneur, and space-tech innovator working at the intersection of biotechnology, nanomedicine, and orbital manufacturing.Dr. King is the Co-Founder and CEO of BioOrbit ( https://www.bioorbit.space/ ), a pioneering company developing pharmaceutical manufacturing platforms in microgravity with the goal of revolutionizing cancer treatment. BioOrbit is focused on producing next-generation medicines in space - particularly highly structured biologics and crystallized therapeutics that may be difficult or impossible to manufacture optimally on Earth due to gravity-driven limitations. The company is preparing for a major in-orbit demonstration mission connected to the International Space Station and upcoming launch activity in 2026.Dr. King earned her Ph.D. in Nanomedicine and Chemistry from the University of Cambridge, where her research focused on self-assembling nanoparticle systems for biosensing and precision medicine applications in collaboration with AstraZeneca. Her work spans nanotechnology, drug delivery, materials science, and pharmaceutical engineering.Beyond the lab, Dr. King has built a remarkably interdisciplinary career. She trained as an officer cadet with the Royal Air Force, interned with NASA Goddard Space Flight Center on the Curiosity Rover's Sample Analysis at Mars program, studied at the International Space University, and has become a leading advocate for using space technology to benefit humanity on Earth.Dr. King is also a passionate science communicator and STEM advocate, serving as a Tech She Can Ambassador and helping inspire the next generation of women entering science and technology fields.Dr. King has been recognized as an Everywoman in Tech Innovator Award winner and one of Codex World's Top 50 Innovators - and today, she joins us to discuss one of the most fascinating frontiers in medicine: manufacturing pharmaceuticals in space.#SpacePharma #BioOrbit #KatieKing #SpaceMedicine #Microgravity #CancerResearch #Biotech #FutureOfMedicine #SpaceTech #OrbitalManufacturing #Nanomedicine #LongevityScience #ISS #DrugDiscovery #CancerTherapy #SpaceBiology #Pharmaceuticals #Innovation #DeepTech #ProgressPotentialPossibilitiesSupport the show

Hosts Heather and Lauren are joined by Leslie Isenhour, Dean of Biotechnologies and North Carolina BioNetwork Capstone Center at Wake Tech Community College. With the growing demand for life sciences talent in North Carolina, Dean Isenhour shares how Wake Take is preparing the community through customized training programs, apprenticeships, and early exposure at the high school level. We discuss what draws major companies to the region and how community colleges partner with industry to close skill gaps, as well as the role of workforce development in supporting continued growth in biopharmaceutical manufacturing. Tune in to hear how education, infrastructure, and community investment come together to build a strong and sustainable talent pipeline in North Carolina!

Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing progress and risking critical quality attributes in monoclonal antibody development.David Brühlmann breaks down a practical, parallel framework for rapid compound screening that addresses interaction effects, masking, and data quality. Methods proven in challenging biosimilar development programs.Topics discussed:The historical bottleneck of one-at-a-time screening in drug discovery and the impact of high throughput methods (01:04)Problems with both one-factor-at-a-time and large design of experiments approaches when handling many variables (02:10)Description of the parallel group method: splitting 17 quality modulating compounds into five biologically relevant groups and running experiments in parallel (06:09)How grouping compounds by biological mechanism improves interpretability and experimental design (06:43)Strategies for minimizing dilution effects, toxicity risks, and masking in multi-factor screens (08:24)The importance of multivariate analysis: using principal component analysis (PCA), Mahalanobis distance, and decision trees to interpret and select optimal experimental conditions (10:31)Real-world outcomes: identifying optimal compound combinations in just two rounds of screening (15:20)Reflections on the evolving role of hybrid modeling and machine learning in biosimilar process optimization (15:54)In Part 2, the focus shifts to a hands-on approach, covering how to design compound groups based on biology, set concentration ranges without compromising data quality, and execute a 96-well screen with the rigor the method demands. It also highlights three key aspects that would be approached differently if the study were conducted today.Strategic insight:Effective compound screening shifts from one-at-a-time testing to biology-driven parallel grouping combined with multivariate analytics, enabling faster identification of optimal combinations while preserving data quality and capturing interaction effects.If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.If you're interested in hybrid modeling, here's what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian FeidlEpisodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi QuintEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.Support the show

In this episode of The Crop Science Podcast Show, Dr. Bob Stupar from the University of Minnesota explores soybean genomics, gene editing, and genomic selection in modern breeding. He explains how markers improve selection efficiency, why SCN resistance requires a multi-gene approach, and what the five-year strategic plan means for the soybean genomics community. Listen now on all major platforms!"The ability to use genomic information to predict and improve selection across entire breeding populations is growing, and even minor-effect genomic regions are becoming targets for practical breeding."Meet the guest: Dr. Bob Stupar is a Professor in the Department of Agronomy and Plant Genetics at the University of Minnesota. His research focuses on molecular genetics and genomics of legume crop species, including soybean and pea, with primary interests in the genetic basis of natural and induced phenotypic variation, developing novel genetic resources, and using genomic strategies for trait improvement.Liked this one? Don't stop now — Here's what we think you'll love!What you will learn:(00:00) Highlight(00:34) Introduction(04:20) Background(05:54) Genetics vs. genomics(10:11) Genomics in breeding(16:58) Biotechnology and GMOs(22:01) Strategic planning(27:39) Future of genomics(29:53) Final questionsThe Crop Science Podcast Show is trusted and supported by innovative companies like:- Loam Bio

Join us in this episode as Tyler Korman, the Chief Scientific Officer and Co-Founder of eXoZymes, explains how their approach to AI-enhanced, cell-free enzyme technology is changing the way chemicals are produced… Hit play to discover: How enzymes are produced in large quantities. The ways that enzymes are used in everyday life.  The role that the microbiome plays in enzyme balance.  How sequencing data contributes to the creation of new compounds.  Tyler co-founded eXoZymes with Paul Opgenorth, building on research from the Jim Bowie Lab at UCLA. His expertise includes cell-free biomanufacturing, enzyme engineering, and AI-driven design. His work focuses on creating more efficient and sustainable methods for producing complex compounds by operating enzymes outside of living cells. To learn more about Tyler and his work, connect with him on LinkedIn!

Proposez votre expertise : https://tally.so/r/GxBO6zListe d'attente de la Guilde Tinctoriale : https://artecovert.kit.com/2a4a79a072Quelle est la véritable couleur de la nature et comment peut-elle transformer notre monde ? Dans cet épisode captivant du podcast ArtEcoVert, nous avons le plaisir d'accueillir Pauline Leroux, ingénieure agronome passionnée par la couleur végétale et les plantes tinctoriales. Elle nous dévoile les secrets de la Guilde, une initiative novatrice qui vise à fédérer et démocratiser l'utilisation de la couleur végétale. Avec une approche bienveillante et engagée, Pauline nous plonge dans l'univers fascinant des couleurs naturelles et nous explique comment ce projet ambitieux peut révolutionner le secteur.La Guilde repose sur plusieurs piliers fondamentaux, notamment un réseau communautaire dynamique, des formations continues de qualité et un accompagnement sur mesure pour les professionnels du secteur. Pauline souligne l'importance cruciale d'un partage des connaissances et de l'entraide entre les artisans et les agriculteurs, qui font face à de nombreux défis dans leur quête de pérennité. "La couleur végétale ne doit pas être un luxe, mais un droit accessible à tous", déclare-t-elle, mettant en lumière l'engagement de la Guilde à rendre la couleur végétale accessible à tous.Au fil de l'épisode, nous découvrons comment la formation est la clé pour surmonter les obstacles entrepreneuriaux et assurer la durabilité des activités liées à la couleur végétale. Pauline évoque les différentes expertises qui seront mises à disposition des membres de la Guilde, afin de les aider à développer leurs compétences et à vivre pleinement de leur passion. Avec des discussions techniques enrichissantes et des partages d'expériences inspirants, cet épisode est une véritable mine d'informations pour tous ceux qui souhaitent s'engager dans une économie durable.En rejoignant la Guilde, les membres auront l'opportunité de bénéficier d'un réseau de soutien solide, de formations adaptées et d'une communauté prête à partager ses expériences. Que vous soyez artisan, agriculteur ou simplement passionné par la couleur végétale, cet épisode d'ArtEcoVert vous inspirera à explorer de nouvelles voies et à vous impliquer dans cette belle aventure.Ne manquez pas cette occasion d'en apprendre davantage sur la couleur végétale et les plantes tinctoriales, et découvrez comment vous aussi, vous pouvez contribuer à une économie plus verte et plus durable. Pour plus d'informations et de ressources utiles, n'hésitez pas à visiter notre site web. Belle écoute !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

As Emerging Technology continues to accelerate across domains like Artificial Intelligence (AI), Biotechnology, & Brain-computer interfaces coverage, humanity may be approaching a threshold that fundamentally redefines what it means to wage war – and what it means to be human.In this episode, host Dr. Arun Seraphin is joined by Dr. Daniel Gerstein, adjunct professor at American University and George Mason University, to discuss Dr. Gerstein's upcoming novel, War Without Humanity: Conflict in the Post-Human Era. Drawing on his extensive background in National Security and Homeland Security, Dr. Gerstein explores a near-future world in which humans, augmented soldiers, and AI-enabled humanoid robots operate side by side on the battlefield – a force he calls the Future Force.The conversation covers the Emerging Technology capabilities at the heart of this transformation and what these developments in Artificial Intelligence (AI) and Biotechnology mean for ethical military doctrine, arms control, and international law in an evolving National Security landscape.Be sure to follow us on social media for updates, early access to upcoming events, inside scoops, & more:LinkedIn: https://bit.ly/4htROo0Twitter: https://bit.ly/48LHAx3Facebook: https://bit.ly/47vlht8 And for more podcasts, articles, & publications all things emerging tech, check out our website at: https://bit.ly/47oA5K1 #EmergingTech #AI #BioTechnology #FutureForceKeywords:-            Emerging Technology-            Artificial Intelligence (AI)-            Biotechnology-            National Security-            Homeland Security-            Future Force

Êtes-vous prêt à plonger dans l'univers fascinant de la couleur végétale et à découvrir comment la nature peut transformer notre approche de la teinture ? Dans cet épisode captivant du podcast ArtEcoVert, nous avons le plaisir d'accueillir Pauline Leroux, ingénieure agronome et fervente défenseure de la couleur végétale. Pauline nous dévoile les objectifs ambitieux de la guilde dédiée à la couleur du vivant, une initiative qui vise à fédérer les passionnés et à démocratiser l'accès à la couleur végétale. Au cœur de cette conversation, nous explorons le concept de la guilde, qui se veut un véritable réseau de connaissances et d'expertise. Pauline explique comment cette communauté a pour mission de créer une bibliothèque vivante, un espace où les informations validées par des experts et des professionnels du secteur seront accessibles à tous. Imaginez un lieu où chaque passionné de couleur végétale peut trouver des réponses à ses questions, échanger des idées et enrichir ses connaissances ! Pauline insiste sur l'importance de partager des connaissances fiables et d'encourager les échanges entre les membres. Elle aborde également la nécessité d'avoir des experts au sein de la guilde pour répondre aux questions techniques et soutenir ceux qui débutent dans le domaine de la teinture végétale. Avez-vous déjà rêvé de maîtriser l'art de la teinture avec des plantes tinctoriales ? Cet épisode est fait pour vous ! En conclusion, Pauline invite chaleureusement nos auditeurs à rejoindre cette initiative passionnante et à explorer les nombreux épisodes précédents du podcast ArtEcoVert. Ne manquez pas cette occasion unique d'enrichir votre savoir sur la couleur végétale et de faire partie d'une communauté engagée et passionnée. Ensemble, nous pouvons redécouvrir les merveilles des plantes tinctoriales et leur impact sur notre environnement. Pour en savoir plus sur la guilde et les ressources qu'elle propose, n'hésitez pas à consulter les liens utiles mentionnés dans l'épisode. Belle écoute et à très bientôt pour de nouvelles découvertes colorées avec ArtEcoVert ! ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

En savoir plus : https://artecovert.kit.com/2a4a79a072Savez-vous que la couleur végétale pourrait bien être l'avenir de l'industrie textile face aux défis environnementaux actuels ? Dans cet épisode captivant du podcast ArtEcoVert La voix de la couleur végétale et des plantes tinctoriales, nous avons le plaisir d'accueillir Pauline Leroux, ingénieure agronome passionnée et experte en couleurs végétales. Elle nous plonge dans l'univers fascinant de la filière teintoriale, en mettant en lumière les évolutions récentes et les défis qui se présentent. Pauline nous dévoile un projet innovant qui vise à créer un outil de collaboration pour fédérer les acteurs de la couleur végétale. Cet outil permettra de sortir de l'isolement et de mutualiser les ressources, favorisant ainsi un écosystème plus solidaire et durable. Elle nous rappelle que les colorants de synthèse, dérivés du pétrole, subissent les effets néfastes de la crise économique, ce qui ouvre une porte d'opportunité pour les colorants naturels. Dans cet épisode, Pauline souligne l'importance cruciale de la biodiversité et des plantes teintoriales qui, grâce à leur faible besoin en intrants, contribuent à la préservation de notre environnement. Elle affirme avec conviction : "La couleur végétale n'est pas seulement une alternative, c'est un choix conscient pour un avenir durable. " Ce témoignage passionnant nous invite à réfléchir sur notre consommation et sur les impacts de nos choix sur la planète. En fin d'épisode, Pauline lance un appel à l'action pour structurer davantage la filière et mobiliser les acteurs autour de la couleur végétale. Elle nous encourage à nous engager activement dans cette démarche, car chaque petit geste compte dans la transition vers une industrie plus verte. Ne manquez pas cette discussion enrichissante où l'expertise de Pauline se mêle à des partages d'expériences et à des réflexions techniques sur l'avenir de la teinture naturelle. ArtEcoVert est votre rendez-vous incontournable pour explorer les enjeux de la couleur végétale et des plantes tinctoriales, tout en découvrant des solutions durables pour notre planète. Pour en savoir plus sur les projets de Pauline et les initiatives autour de la couleur végétale, n'hésitez pas à consulter les liens utiles que nous mettons à votre disposition. Rejoignez-nous pour cette belle aventure colorée et engagée ! Belle écoute ! ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

Retrouvez Alison Fleck : https://savonnier-patissier.com/Saviez-vous que les couleurs végétales peuvent transformer non seulement nos créations, mais aussi notre rapport à la nature ? Dans cet épisode d'ArtEcoVert, la voix de la couleur végétale et des plantes tinctoriales, Pauline Leroux, ingénieure agronome et passionnée de couleur végétale, a le plaisir de recevoir Alison Fleck, la créatrice de la Savonnerie Baba. Ensemble, elles plongent dans l'univers captivant des couleurs végétales et des plantes tinctoriales, révélant des secrets et des techniques qui vous inspireront à repenser votre approche de l'artisanat.Alison, qui a débuté sa carrière comme pâtissière, a su réinventer son parcours en intégrant des pigments végétaux dans ses créations de savons artisanaux. Elle partage avec nous son expérience unique, les défis rencontrés et les joies de travailler avec des matériaux naturels. Vous découvrirez comment la saponification à froid permet de préserver les bienfaits des plantes tout en respectant l'environnement. Alison insiste sur l'importance de l'ergonomie dans le travail artisanal, un aspect souvent négligé, mais essentiel pour créer des produits de qualité qui respectent à la fois l'artisan et la planète.Dans cet échange riche et inspirant, Pauline et Alison abordent également la transmission du savoir-faire à travers des ateliers, des livres, et des collaborations avec d'autres artisans. Vous apprendrez comment ces initiatives contribuent à soutenir les filières agricoles locales et à promouvoir une consommation plus responsable. "Chaque couleur végétale raconte une histoire", souligne Alison, rappelant ainsi l'importance de valoriser notre patrimoine naturel.Ne manquez pas cet épisode d'ArtEcoVert, où la couleur végétale et les plantes tinctoriales prennent vie à travers des discussions techniques, des partages d'expériences et des conseils pratiques. Que vous soyez un passionné d'artisanat, un amoureux de la nature ou simplement curieux d'en savoir plus sur les alternatives durables, cet épisode est fait pour vous. Rejoignez-nous pour découvrir comment intégrer ces pratiques éthiques dans votre quotidien et contribuer à un avenir plus vert.Pour plus d'informations sur les couleurs végétales et les plantes tinctoriales, n'hésitez pas à consulter notre site et nos ressources utiles. En attendant, belle écoute !ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech's most complex transformations.  After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation.  The conversation dives into Vir Bio's next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment.  They also discuss Vir Bio's advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company's growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology.  Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth.  This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode  Timestamps  00:00 – Introduction and Vir's transformation story  00:40 – Marianne De Backer's 30+ year pharma journey  02:42 – Vir's origins and post-COVID strategic pivot  04:42 – Taking over as CEO during a crisis  06:33 – Lessons from the biotech downturn (“biotech winter”)  08:56 – Astellas partnership and T-cell engager strategy  09:52 – ProXtend platform: masked T-cell engagers explained  13:24 – Clinical data, safety, and tumor targeting  15:32 – Integrating new teams and scientific expertise  17:38 – Expanding the pipeline (HER2, EGFR, oncology)  19:50 – Hepatitis delta program and commercialization plans  22:11 – Funding strategy and biotech market outlook  25:37 – FDA interactions and regulatory perspective  28:13 – AI in drug discovery and clinical trials (Daisy platform)  31:34 – Culture: grit, ingenuity, collaboration, authenticity  34:21 – Personal reflections and leadership mindset  35:46 – Closing thoughts  Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Marianne De Backer;  LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/  Website: https://www.vir.bio/      Follow IDEA Pharma On;  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Show Notes 24 April 2026XM30 Lynx: The US Army's New 50mm Cannon‑Powered Robot War Machine Alex Barrientos GadgetReview.com https://www.gadgetreview.com/xm30-lynx-the-us-armys-new-50mm-cannon%e2%80%91powered-robot-war-machineNew software could cut cooling energy use by 25% in data centers Ty Tkacik PennState website https://www.psu.edu/news/research/story/new-software-could-cut-cooling-energy-use-25-data-centersChemists make hydrogen from breadcrumbs in groundbreaking reaction that could replace some fossil fuels Victoria Atkinson LiveScience.com https://www.livescience.com/chemistry/chemists-make-hydrogen-from-breadcrumbs-in-groundbreaking-reaction-that-could-replace-some-fossil-fuelsGraphene 'scaffold' recruits bone cells and helps the body repair fractures Robert Egan Phys.org https://phys.org/news/2026-04-graphene-scaffold-bone-cells-body.htmlEco-Friendly Laser Method Turns Leather into Flexible Wearable Tech Tomorrow's World Today https://www.tomorrowsworldtoday.com/sustainability/eco-friendly-laser-method-turns-leather-into-flexible-wearable-tech/KAIST Develops Electrode Technology Achieving 86% Efficiency for Converting CO₂ into Plastic Precursors Korea Advanced Institute of Science and Technology website https://www.kaist.ac.kr/newsen/html/news/?mode=V&mng_no=60350Scientists gene hacked a plant so it grows five types of psychoactive drugs at once Victor Tangermann Futurism.com https://futurism.com/health-medicine/gene-hacked-plant-grows-five-types-psychedelic-drugsScientists Just Discovered There's Actually Something Faster than the Speed of Light Darren Orf Popular Mechanics https://www.popularmechanics.com/science/a70885429/darkness-faster-than-light/

Michael Jewett is a pioneer of cell-free biotechnology. Instead of using living microbes as factories, he uses their internal molecular machinery to make valuable proteins, medicines, diagnostics, and other chemicals. Jewett recently used the technique for vaccine production in an approach that could produce up to 150,000 doses from one liter. He believes cell-free biotech could democratize the production of essential medicines, improve water safety, and help convert atmospheric carbon into useful products, among other promising possibilities. “It's just-add-water biotechnology,” Jewett tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Michael Christopher Jewett Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces Mike Jewett, a professor of bioengineering and chemical engineering at Stanford University. (00:03:23) What Is Cell-Free Biotechnology? Using the internal machinery of cells without the cells themselves. (00:04:20) Removing “Evolutionary Baggage” Why cells' natural priorities can conflict with engineering goals. (00:07:41) Advantages of Cell-Free Systems From large-scale production to decentralized, on-demand manufacturing. (00:11:40) Making Proteins Outside Cells How DNA instructions are used to produce functional proteins. (00:13:49) Biosensors for Water Safety Detecting contaminants like lead using engineered proteins. (00:17:05) Engineering Better Sensors Improving sensitivity and selectivity through protein design. (00:20:33) AI in Bioengineering How data and models accelerate discovery and design. (00:23:22) Sustainability & Carbon Capture Turning atmospheric carbon into useful chemicals. (00:26:18) Building New Biological Pathways Combining chemistry and biology to create novel production systems. (00:27:54) From Molecules to Materials How acetyl-CoA enables fuels, plastics, and other products. (00:30:51) Teaching Biotechnology Making biotech accessible through hands-on, “just-add-water” kits. (00:33:12) Future In a Minute Rapid-fire Q&A: innovation, collaboration, and the future of biotech. (00:35:32) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

First up on the podcast, freelance science and environmental journalist Quentin Septer joins host Sarah Crespi to talk about a controversial uranium mine getting fast-tracked in South Dakota. Septer chatted with locals, scientists, and regulators to learn more about the geology of the region and the promise of cleanup after the miners go home. Next on the show, looking at cells that don't get cancer. Giulio Ciucci, a postdoctoral researcher at the International Centre for Genetic Engineering and Biotechnology, talks about the infrequency of heart cancer and how the mechanical load that heart cells endure makes them resist turning cancerous. This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices

Artificial intelligence (AI) is impacting nearly everything in society these days, including the world of biotechnology and life sciences. In this episode of IP Talk with Wolf Greenfield, Janice Vatland, a Shareholder in Wolf Greenfield's Biotechnology practice, explains important IP considerations for turning groundbreaking discoveries that utilize AI into lasting business value.With nearly 25 years of experience, Janice works with clients of all sizes, including universities, start-ups, and small to mid-sized companies. She also serves as Chair of Wolf Greenfield's PTO Practice Committee.Here are a few highlights from the conversation:00:58 - Janice describes her practice at Wolf Greenfield01:57 - The factors that led Janice from her work in science to IP law05:25 - Janice explains how AI is being used in biotech today06:51 - AI systems cannot be listed as inventors, and that creates challenges for companies using AI08:05 - Additional issues with AI that companies need to be mindful of10:54 - Companies are eager to use AI to gain a competitive advantage11:53 - Key IP protection considerations for companies using AI 13:16 - As patents on AI-derived drugs become more common, new legal challenges may arise as companies seek to defend their portfolios16:49 - With science, technology, and AI all moving and changing so quickly, it's critical for companies to constantly be monitoring and updating their IP strategies 

First up on the podcast, freelance science and environmental journalist Quentin Septer joins host Sarah Crespi to talk about a controversial uranium mine getting fast-tracked in South Dakota. Septer chatted with locals, scientists, and regulators to learn more about the geology of the region and the promise of cleanup after the miners go home. Next on the show, looking at cells that don't get cancer. Giulio Ciucci, a postdoctoral researcher at the International Centre for Genetic Engineering and Biotechnology, talks about the infrequency of heart cancer and how the mechanical load that heart cells endure makes them resist turning cancerous. *CORRECTION: In the on this site summary in this episode, the book author in the review by Kai Kupferschmidt was listed incorrectly. The correct information is: True Color by Kory Stamper, Knopf, 2026.   This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices

As technology continues to recover, growth is back in the spotlight. Gene explores how investors are taking on more risk in search of greater rewards—and how this shift is influencing key market categories. Biotechnology is one area showing signs of leadership, with ripple effects across the healthcare sector. Listen in for a deeper look at these developing trends.

Show Notes 17 April 2026Researchers Develop 3D Printed Lab-Grown Ear Cartilage3DPrinting.com https://3dprinting.com/news/researchers-develop-3d-printed-lab-grown-ear-cartilage/3D Printed Ear Video ETH Zurich YouTube https://www.youtube.com/watch?v=01U6KC35dKwNovel prosthetic design combines AI and 3D printing to improve fitRobert Egan MedicalXpress.comhttps://medicalxpress.com/news/2026-03-prosthetic-combines-ai-3d.htmlAI blood test finds silent liver disease years before symptomsJohns Hopkins MedicineScienceDaily.com https://www.sciencedaily.com/releases/2026/03/260305223204.htmAI Liver Disease Research Paper Science Translational MedicineScience.org https://www.science.org/doi/10.1126/scitranslmed.adw2603The Future of Mobility: How Advanced Robotic Prosthetics are Restoring Touch and MotionKevin Famuyiro Los Angeles Times https://www.latimes.com/doctors-scientists/innovations/technology/story/advanced-robotic-prosthetics-surgery-sensors-bionic-limbsInside world's first hydrogen-powered cruise scheduled to set sail this yearErin Deborah WaksMSNhttps://www.msn.com/en-ae/travel/cruises/inside-world-s-first-hydrogen-powered-cruise-scheduled-to-set-sail-this-year/ar-AA1ZspvQLife May Have Started as Sticky Goo, Long Before Cells Even ExistedJess CockerillScienceAlert.com https://www.sciencealert.com/life-may-have-started-as-sticky-goo-long-before-cells-even-existedBioengineered neuronal ‘circuit board' mimics conditions of the human brainBiotech-today.comhttps://biotech-today.com/bioengineered-neuronal-circuit-board-mimics-conditions-of-the-human-brain/Chinese Scientists Create ‘Organic' Electric Car Batteries Using PlasticNeha BhatiaGreenMatters.comhttps://www.greenmatters.com/pn/chinese-scientists-create-organic-electric-car-batteries-using-plastic-in-breakthrough-research

Quelle est la couleur qui évoque en vous une émotion particulière ? Dans cet épisode captivant d'ArtEcoVert La voix de la couleur végétale et des plantes tinctoriales, Pauline Leroux reçoit François-Charles Plucain, un expert passionné qui nous entraîne dans un voyage fascinant à la croisée des chemins entre la couleur et le parfum. François-Charles, dont le parcours impressionnant va des études en art plastique à l'innovation dans le conseil couleur, nous dévoile sa méthode unique de chromaturgie, une technique révolutionnaire qui transforme les couleurs en parfums d'intérieur.Au fil de cette discussion enrichissante, ils explorent ensemble comment la perception des couleurs influence nos émotions et comment ces nuances peuvent être habilement utilisées pour créer des ambiances harmonieuses dans nos espaces de vie. François-Charles insiste sur l'importance de l'écoute dans son métier de coloriste, soulignant que chaque couleur porte en elle une signification culturelle et émotionnelle qui mérite d'être décodée.Les tendances actuelles en matière de couleur sont également abordées, notamment le retour en force des teintes terreuses et des nuances inspirées par la nature. Cette conversation met en lumière la nécessité de rétablir une connexion authentique avec les couleurs végétales et leur potentiel inestimable dans le design d'intérieur. En effet, les couleurs tinctoriales, issues de notre environnement naturel, offrent une alternative riche et durable face aux couleurs synthétiques souvent utilisées.Alors que nous nous interrogeons sur notre rapport à la couleur, François-Charles nous rappelle que la beauté réside dans la diversité des teintes et des senteurs que nous pouvons intégrer dans notre quotidien. Cette approche holistique est essentielle pour créer des espaces qui résonnent avec notre être intérieur et favorisent notre bien-être.Ne manquez pas cette occasion d'élargir vos horizons sur le thème de la couleur et du parfum. Pour découvrir plus sur François-Charles Plucain et son travail innovant, visitez [lien utile].Préparez-vous à une belle écoute et à une immersion sensorielle unique avec ArtEcoVert La voix de la couleur végétale et des plantes tinctoriales. Pauline vous invite à plonger dans cette aventure colorée et parfumée qui pourrait bien transformer votre perception des couleurs dans votre vie quotidienne.ArtEcoVert informe et inspire celles et ceux qui veulent repenser la couleur autrement, et les accompagne dans leur transition vers une couleur plus durable — avec des témoignages concrets le jeudi

When Sci-Fi Becomes the Business Plan A Brand Highlight Conversation with Jacob Flores, Head of Research at Type One Ventures There is a version of investing that asks what the return will be. And then there is the version that asks what kind of future the investment makes possible. Jacob Flores, Head of Research at Type One Ventures, is working firmly in the second category. Type One Ventures takes its name from the Kardashev Scale — a framework developed by Soviet astrophysicist Nikolai Kardashev that ranks civilizations by their level of technological advancement. A Type One civilization has mastered its home planet and is beginning to extend its reach beyond it. That is the destination this firm is trying to fund. Flores, a former engineer and product manager with roughly a decade of experience across industries, leads the research function at Type One with a focus on AI, neurotech, and biotechnology. The firm's investment lens is as much philosophical as it is financial. Type One looks for platform builders — companies whose core technology can be stacked across multiple applications, cultivating new marketplaces and entirely new categories of industry. Manufacturing in space is one clear example: in microgravity, it becomes possible to grow proteins, print circuits, and develop materials that cannot be produced the same way on Earth — yet those products have immediate, tangible value back on the ground. The thesis extends well beyond orbit. Type One is also backing neurotechnology companies working to restore vision and movement for people who have lost those abilities, and longevity research aimed at extending healthy human life. Flores frames these not as moonshots for their own sake, but as the new foundation layer for an entirely new level of global industry. This is a Brand Highlight. A Brand Highlight is a ~5 minute introductory conversation designed to put a spotlight on the guest and their company. Learn more Host Marco Ciappelli, Co-Founder, ITSPmagazine Guest Jacob Flores, Head of Research, Type One Ventures Resources Type One Ventures Type One Ventures on LinkedIn Want to tell your story? Full Length Brand Story Brand Spotlight Story Brand Highlight Story Keywords: Jacob Flores, Type One Ventures, Marco Ciappelli, brand story, brand marketing, marketing podcast, brand highlight, space technology, deep tech, venture capital, multi-planetary civilization, Kardashev Scale, manufacturing in space, neurotech, longevity, AI, biotechnology, frontier technology, space investing, human longevity, platform builders Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

April is Earth Month, and in appreciation of the plant life all around us, we're re-running a conversation we had with Beth Sattely last year on the future of plant chemistry. Beth reminds us that plants are more than food or pretty things to look at — they have the potential to help us fight climate change or even cancer. We hope you'll take another listen and join us in learning more about how plants can positively impact environmental and human health. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Elizabeth Sattely Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Beth Sattely, a professor of chemical engineering at Stanford University. (00:01:28) Path to Plant Metabolism How chemistry and gardening led to a career in plant science. (00:02:12) Environmental & Human Health Using plants to improve both the planet and people's well-being. (00:03:11) Engineering Climate-Resilient Crops Making crops more sustainable and nutritious amid global change. (00:04:16) Old vs. New Crop Engineering Comparing traditional breeding with modern molecular tools. (00:06:22) Industry & Long-Term Food Security The gap between short-term market goals and long-term environmental needs. (00:07:31) Tomato Chemistry Tomatoes reveal how plants produce protective molecules under stress. (00:10:44) Plant “Vaccines” & Immune Signaling How plants communicate threats internally and mount chemical defenses. (00:12:32) Citrus Greening & Limonoids The potential role of limonoid research on citrus greening. (00:15:17) Plants Making Medicine How plants like Yew trees naturally produce cancer drugs like Taxol. (00:19:37) Diet as Preventative Medicine Identifying plant molecules to understand their preventative health effects. (00:22:54) Food Allergies & Plant Chemistry Why the immune system tolerates some foods and rejects others. (00:25:00) Understanding Tolerance in Immunity Possibility of reintroducing tolerance through partial molecular exposure. (00:26:20) Engineering Healthier Plants Potential for designing plants to enhance micronutrient content. (00:27:58) Training the Next Generation Beth celebrates her students' role in shaping a sustainable future. (00:28:57) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Är transhumanisternas vision på väg att bli verklighet? Lyssna på alla avsnitt i Sveriges Radios app. Hjärnchip har länge utvecklats inom forskningen, men nu testas nya system i allt fler verkliga försök på människor. För vissa handlar det om hoppet att återfå funktioner som gått förlorade. För andra handlar det om något mer: att förbättra människan och tänja på gränsen för vad kroppen och hjärnan klarar av.Men vem tjänar på den utvecklingen? Och vad riskerar vi att förlora när människans inre blir nästa tekniska plattform?Programledare och producent: Jennifer Sjöblom och Erik PeterssonMedverkande:Ingrid Dunér - Doktor i idé- och lärdomshistoria vid Lunds UniversitetAnders Sandberg - Doktor i datavetenskap och forskare vid Institutet för framtidsstudierMaria Asplund - Professor i bioelektronik och mikrosystemteknik för bioelektronik och neuroteknologi på ChalmersAnna Wexler - Neuroetiker och biträdande professor i medicinsk etik och hälsopolitik vid universitetet i PennsylvaniaUniversity of PennsylvaniaLiam Drew - Brittisk vetenskapsjournalist som skriver för bland annat Nature och The GuardianBöcker:Artificial you: A.I. and the Future of Your Mind av Susan SchniderThe battle for your brain av Nita FarahanyLiv 3.0 av Max TegmarkHomo Deus av Yuval Noah HarariAndra tryckta källor:Rapporten Mind Control Past and Future från Harvard Kennedy School av Lukas J MeierWHO rapporten Landscape analysis of the opportunities and challenges for neurotechnology in global healthFOI-rapporten Det förflutna och framtiden som formar nuet. En systemkartläggning och riskbedömning av svensk bioteknikKällor i urval:Vox: Unexplainable: Sorry we left an implant in your brainNature: Neuronal ensemble control of prosthetic devices by a human with tetraplegiaBlackrock Neurotech: Tether invested $200M in Blackrock Neurotech, accelerating development and commercialization of implantable BCI technologyNature: Abandoned: The human cost of neurotechnology failureReuters: Exclusive: Musk's Neuralink has faced issues with its tiny wires for years, sources sayReuters: Elon Musk's Neuralink says it has 21 participants enrolled in trialsNature: AI & robotics briefing: Lack of transparency surrounds Neuralink's ‘brain-reading' chipNature: A nonsurgical brain implant enabled through a cell–electronics hybrid for focal neuromodulationNature: Neuralink brain chip: advance sparks safety and secrecy concernsNature: The business of brain-computer interfacesMIT news: New therapeutic brain implants could defy the need for surgerySVD: Elon Musks hjärnchip förändrade hans livVetenskapsradion nyheter: Chip i hjärnan på människor har blivit verklighet – så ska de användasFilosofiska rummet: Transhumanismen – en möjlighet att optimera människan eller ett hot mot det mänskliga? 2020The infinite monkey cage: Mind-reading computers 2025Paradiso: Sätt in ett chip i djupaste hjärnan - framtidens antidepp 2025I hjärnan på Louise Epstein: Därför drömmer Elon Musk om chip i hjärnan 2023The Guardian: Prof Nita Farahany: ‘We need a new human right to cognitive liberty'Springer: Julian Huxley, Evolutionism and the History of TranshumanismThe Conversation: Freedom of thought is being threatened by states, big tech and even ourselves. Here's what we can do to protect itTime: Computer Chips in Our Bodies Could Be the Future of Medicine. These Patients Are Already ThereStanford Medicine: Eye prosthesis is the first to restore sight lost to macular degenerationNew York Times: Big Tech Wants Direct Access to Our BrainsNature: The business of brain–computer interfacesBBC: The man with a mind-reading chip in his brain - thanks to Elon MuskThe Conversation: Ghost in the Shell thrills but ducks the philosophical questions posed by a cyborg futureThe Conversation: Transhumanism: billionaires want to use tech to enhance our abilities – the outcomes could change what it means to be humanEthics, Medicine, and Public Health: Transhumanism: Towards a new Adam?Journal of Neuroscience Methods: DARPA-funded efforts in the development of novel brain–computer interface technologiesNATO: Summary of NATO's Biotechnology and Human Enhancement Technologies StrategyThe Conversation: The brain is the most complicated object in the universe. This is the story of scientists' quest to decode it – and read people's mindsNew York Times: A.I. Is Getting Better at Mind-ReadingFinancial Times: The transformative potential of computerised brain implantsNew York Times: Should You Add a Microchip to Your Brain?The Guardian: Investors' ‘dumb transhumanist ideas' setting back neurotech progress, say expertsEFN: Ingrid Dunér: Teknikens löfte, människans ödeMusik:Cliff Martinez - Save Some For UsCliff Martinez - Don't Blow ItCliff Martinez - Placental RepairKid Loco - Theme from the Graffiti ArtistSilver Maple - Particle EmissionStar Hopper - Through The HeliopauseThomas Newman - The Mouse On The MileBen Jordan - AngelsJon Brion - You LearnAlberto Iglesias - TreasureCliff Martinez - I'm In The PinkNew Order - Blue MondayBlue Dot Sessions - Lemon and MelonMartin D. Fowler - 1 Ships XIIAlexandre Desplat - SyrianaHans Zimmer - Afraid Of TimePaul Leonard Morgan - A Touch of InsanityCliff Martinez - Never Read HimOchre - A Midsummer Nice DreamCliff Martinez - Speight Lived HereCliff Martinez - I'm SickMarcus Bagalà - Duco in Mara's RoomCliff Martinez - Rubber HeadMarcus Bagalà - Boxes: It Goes Like ThisCliff Martinez - Same SweatpantsBen Salisbury, Geoff Barrow - Setting the Eagle FreeCliff Martinez - Searching for SomethingBen Salisbury, Geoff Barrow - Dream RealityCristobal Tapia De Veer - The PublicVince Pope - Who Are YouHelios - Even TodayJustin Hurwitz - QuarantineDaniel Hart - Critical Issue for the FutureKraftwerk - The Robots

You probably haven't grown any gene edited crops yet, but they're coming.

Podcast family we've all heard the rumors that oursmartphones are “LISTENING TO US”. Well, some of that is actually true, and trust me I'm not a conspiracy theorist. Our smartphones are capable of remarkable things. A new publication from the Green journal (released ahead ofprint on 03/05/2026 ) is proposing that it may now be able to detect fetal movement, fetal breathing, and even fetal hiccups when placed over the abdomen! Yep, it's not science fiction... it's science innovation. While this is not ready for prime time just yet, the science is absolutely astounding. In this quicky episode we will briefly summarize a fascinating new innovative study which proposes that our iPhones may be able to be a fetal movement detector.1.     Moise, Kenneth Jr MD; Gaither, Kelly PhD;Madden-Rusnak, Anna PhD; Lowry, Kathy RN, MSN; Hutson, Emily RN, MSN; Bruns, Danielle RDMS; Valero, Reinaldo MD, RDMS. Smartphone Detection of FetalMovements Using Artificial Intelligence. Obstetrics & Gynecology ():10.1097/AOG.0000000000006228, March 5, 2026. | DOI:10.1097/AOG.00000000000062282.     Lai J, Woodward R, Alexandrov Y, et al Performanceof a Wearable Acoustic System for Fetal Movement Discrimination. PloS One. 2017. 3.     Ashik AK, Gutierrez R, Ashraf F, et al. AMachine Learning Model for Assessing Fetal Health During Pregnancy. Frontiers in Bioengineering and Biotechnology. 2025. 4.     Antepartum Fetal Surveillance: ACOG PracticeBulletin, Number 229. Obstetrics and Gynecology. 2021.5.     Monitoring a Pregnancy at Home With a SmartphoneThis wearable device provides real-time ECG monitoring of a fetus: https://spectrum.ieee.org/pregnancy-heartbeat-monitor-smartphone

Join Dr. Alicia Castillo Holley, Founder and CEO of Wealthing Group, for a candid and critical look at the venture capital industry. With over 30 years of experience and a PhD in Finance, Alicia has spent her career bridging the gap between scientific innovation and commercial success. In this episode, we tackle the existential question: "Can we make Venture Capital work?" From her early days pioneering Chile's first seed fund to her current leadership in Silicon Valley, Alicia explores how her "Wealthing" philosophy can fix the industry's flaws by prioritizing impact, diversity, and long-term socioeconomic development.

Microorganisms may be invisible to the naked eye, but their impact on our planet is enormous. In this episode, Dr. Christopher Garner, assistant professor of biology at Southern Nazarene University, explores the fascinating world of microbiology and the powerful role microbes play in shaping ecosystems, influencing climate processes, and driving scientific innovation. Dr. Garner earned his Ph.D. in microbiology from the University of Oklahoma in 2024, where he taught microbiology and received the 2022 Dodge Family College of Arts and Sciences Dissertation Research Fellowship. His research focuses on methane-oxidizing bacteria, microbial ecology, and the discovery and classification of new bacterial species. In this conversation, we explore: ·       How mosquitoes can spread and interact with different microbiomes. ·       The role microbes play in environmental solutions like wastewater treatment and bioremediation. ·       How microbial communities adapt to environmental change and what that means for future ecosystems. From climate science and sustainability to emerging biotechnology, Dr. Garner explains why microbes are essential to solving some of the world's most pressing challenges. To learn more about Dr. Garner, visit his academic website and his SNU webpage. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 

We're joined by Laura Tripaldi: material scientist, writer, and researcher at the Center for AI and Culture at NYU Shanghai. You probably know her from Parallel Minds: Discovering the Intelligence of Materials (Urbanomic, 2022), an essay in book form that became a phenomenon in theory and art circles. Tripaldi's work challenges one of the strongest contentions within the philosophy computation: that intelligence is substrate-indifferent, that it can scale and migrate independent of what carries it. She argues the opposite, that you cannot separate intelligence from the materials through which it is conveyed.This becomes experimentally clear in her recent essay Substrates Unbound (Antikythera, 2025), where she tracks biocomputing systems like DishBrain — living neuronal cultures interfaced with silicon chips that don't execute pre-given code but reorganize, learn, and adapt. Mouse neurons and human neurons perform differently under the same training conditions. This reframes a central question of the moment: not 'can we scale intelligence,' but which matter are we asking to think, under what energy regime, and at what cost?References:Tripaldi, Laura. Parallel Minds: Discovering the Intelligence of Materials (Urbanomic, 2022).Tripaldi, Laura. "Substrates Unbound" (Antikythera, 2025).Tripaldi, Laura. Soft Futures (newsletter, Substack).Haraway, Donna. A Cyborg Manifesto (1985).Parisi, Luciana. Abstract Sex: Philosophy, Biotechnology and the Mutations of Desire (Continuum, 2004) — source of the concept of hyper nature.Hui, Yuk. The Question Concerning Technology in China (Urbanomic, 2016) — source of the concept of cosmotechnics.Barad, Karen. Meeting the Universe Halfway: Quantum Physics and the Entanglement of Matter and Meaning (Duke, 2007) — onto-epistemology and intra-action.Irigaray, Luce — referenced as an influence on Tripaldi's feminist materialism.Pasquinelli, Matteo. The Eye of the Master: A Social History of Artificial Intelligence (Verso, 2023) — discussed in relation to technology as captured labor; Tripaldi pushes back via the history of automata.Laschi, Cecilia. Soft Robotics Lab, National University of Singapore — pioneer of octopus-inspired soft robotics.Hookway, Branden. Interface (MIT Press, 2014).

Greg Nichols is operations manager in the ORAU health studies program, but he wears a lot of hats. He has become an expert in artificial intelligence and received an ORAU Thought Leadership Research Award to write a chapter on the convergence of AI and biotechnology. Nichols's chapter, “Assessing Governance and Regulatory Frameworks for Converging Technologies: The Case of Artificial Intelligence in Biological Engineering and Design Technologies,” appears in Biotechnology and AI: Technological Convergence and Information Hazards. He says that While biotechnologies are somewhat better regulated and monitored compared to other technologies, artificial intelligence is not, and the combination of these two is certainly not explicitly or fully covered by most existing regulations or risk governance framework. This was an insightful and thought-provoking conversation. To learn more about the chapter Nichols wrote, visit https://link.springer.com/chapter/10.1007/978-3-032-05246-9_8 Find the book at https://link.springer.com/book/10.1007/978-3-032-05246-9

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a powerful conversation at the intersection of biotech innovation, leadership, and personal transformation. Sheila shares the unconventional journey that led her from academic medicine to the forefront of biotechnology—spanning roles at Genentech and Bristol Myers Squibb, founding companies, serving on boards, and recently helping guide Ventus Therapeutics through its acquisition by Lilly. Along the way, she reflects on the lessons she learned building drugs, scaling companies, and navigating the evolving biotech deal environment. The discussion then turns deeply personal as Sheila explores the ideas behind her book “The Mirror Effect,” revealing how self-awareness, supportive networks, and authentic leadership can transform careers—especially for women and underrepresented leaders in science. From overcoming imposter syndrome to building the “CEO Sisterhood” network of women biotech leaders, Sheila shares hard-earned insights on navigating power, culture, and identity in high-stakes industries. For founders, investors, and leaders alike, this episode blends biotech strategy with deeply human lessons on resilience, purpose, and the power of believing in yourself. Biography: SHEILA GUJRATHI, MD, is a biotech entrepreneur, executive, and champion for under- represented leaders. Over the past 25 years, she's had the privilege of developing life-changing medicines for patients with serious diseases while building and running private and public biotech companies—including some exciting exits. Today she's a founder, chairwoman, board director, strategic advisor, and consultant to start-up companies and investment funds. Dr. Gujrathi was the co-founder and former CEO of Gossamer Bio and former Chief Medical Officer of Receptos. Her journey started at Northwestern University, where she earned both her M.D. and biomedical engineering degree, and took her from the halls of Harvard, UCSF, and Stanford to the corporate offices of Fortune 500 companies like McKinsey, Genentech, and Bristol-Myers Squibb. Dr. Gujrathi has earned multiple leadership awards, including AIMBE Fellow, BLOC100 Luminary, Healthcare Technology Report Top 25 Women Leaders in Biotechnology, Corporate Directors Forum Director of the Year, and Fiercest Women in Life Sciences. But what really lights her up is creating the inclusive environments she wished she'd had throughout her career. That's why she co-founded the Biotech CEO Sisterhood, a group of trailblazing female CEOs—because we're all better when we support each other.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Tim Clackson, PhD. Dr Clackson is a biotechnology executive at Kesmalea Therapeutics.Drs Camidge and Clackson discussed Dr Clackson's career journey through the biotechnology field, which began when his innate curiosity about biology and evolution led him to study biochemistry. He then pursued his PhD and was part of the small team that developed antibody phage display libraries, a breakthrough technology that allows scientists to mimic the immune system in a test tube to find specific antibodies. This work was foundational to the discovery of major drugs and contributed to the awarding of a Nobel Prize in 2018.In 1991, Dr Clackson moved to the US to pursue a postdoc at Genentec, where he was inspired by the company's vibrant and optimistic research environment. He then joined Ariad Pharmaceuticals, where he stayed for more than 20 years, evolving from a bench scientist to president of R&D. A major highlight of his tenure was the development of ponatinib (Iclusig) for the treatment of patients with chronic myeloid leukemia. He also navigated significant challenges, including ponatinib's temporary market withdrawal due to safety concerns, which the company eventually resolved by narrowing the drug's clinical application.In the following years, Dr Clackson transitioned into chief executive officer roles at other biotech firms, such as IDRx. He noted that although acquisitions often result in leadership changes—humorously stating, "the higher you are, the quicker you go"—he enjoyed the storytelling aspect of pitching scientific strategies to investors. In the present day, Dr Clackson remains active in the biotechnology industry through board service and entrepreneurship.

HEADLINE: Charles Lieber and the CRISPR Threat. GUEST: Brandon Weichert. SUMMARY: Weichert highlights Charles Lieber's conviction and He Jiankui's unethical gene experiments, illustrating how China exploits dual-use biotechnology to advance military goals and defeat Western rivals.PEKING 1904

The AI-driven future of espionage is here. In a world where China is building super soldiers and weaponizing AI, the battle to protect America's intelligence dominance has never been more critical. Hear from former NGA Chief Technology Officer Dr. Anthony Vitchie as he reveals the chilling realities of the Fourth Intelligence Revolution - from AI-powered cyber attacks to the democratization of super weapons. This is no science fiction - this is the future of global competition, and the stakes have never been higher.Website:  https://www.anthonyvinci.com/ Dr. Vincis substack: https://vascoduarte.substack.com/p/bonus-saving-democracyhow-ai-is-transforming